2.

一线及二线及以上EGFR突变患者临床获益率比较

Clinical benefit rate of Icotinib as fist line, second line and above in the treatment of patients harboring EGFR mutation

Variables DCR	First line (n=134)	Second line and above (n=97)	P
DCR: disease control rate.
1 year benefit ratio	91 (67.9%)	52 (53.6%)	0.027
2 years benefit ratio	25 (18.7%)	9 (9.3%)	0.047